Cardinal Report: Future Bright for Biosimilars

Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumThe future looks strong for biosimilars, particularly in the oncology space, according to a new report from Cardinal Health. The company’s 2026 Biosimilars Report reviewed industry trends, the biosimilars pipeline, and gathered input from 101 oncology, hematology, rheumatology, and ophthalmology practices nationwide.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; fo